PeptiDream Inc (4587)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:PeptiDream Inc (4587) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013468
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PeptiDream Inc (PeptiDream) is a biopharmaceutical company that discovers and develops constrained peptides, small molecule, and peptide-drug conjugate therapeutics. The company develops peptide discovery platform system (PDPS), a peptide generation and selection platform. Its technologies include flexizyme; translation, cyclization, and peptide modifying technologies; and PD display. PeptiDream’s technologies enables the production of peptide libraries for the development of peptide-based products. It offers products for the treatment of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and others. The company collaborates with other biotechnology and drug development companies to receive contracts and research and development support funds, and target proteins. PeptiDream is headquartered in Kawasaki, Japan.

PeptiDream Inc (4587) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PeptiDream Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PeptiDream Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
PeptiDream to Acquire Drug Discovery Research Business from PharmaDesign 12
Private Equity 13
Taiyo Pacific Partners Acquires Minority Stake in PeptiDream 13
Partnerships 14
Bayer and PeptiDream Enter into Partnership 14
PeptiDream and Kleo Pharma Enter into Co-Development Agreement 15
Heptares Therapeutics and PeptiDream Enter into Agreement 16
Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 17
PeptiDream Enters into Agreement with Janssen Pharma 18
PeptiDream Enters into Research Agreement with BIND Therapeutics 19
PeptiDream Enters into Research Agreement with Asahi Kasei Pharma 20
PeptiDream Enters into Agreement with Genentech 21
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 22
Teijin Pharma Enters into Discovery Agreement with PeptiDream 23
PeptiDream Enters into Discovery Agreement with Sanofi 24
PeptiDream Enters into Peptide Discovery Agreement with Merck 25
PeptiDream Expands Drug Discovery Agreement with Novartis 26
PeptiDream Enters into Agreement with Tokyo Metropolitan Institute of Medical Science 27
PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 28
PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 29
PeptiDream Expands Drug Discovery Agreement with Amgen 30
PeptiDream Expands Macrocylic Peptide Drug Discovery Agreement with Novartis 31
PeptiDream Enters into Drug Discovery Agreement with MedImmune 32
PeptiDream Extends Discovery Agreement With Bristol-Myers Squibb 33
PeptiDream Enters into Drug Discovery Agreement with GlaxoSmithKline 34
PeptiDream Enters into Drug Discovery Agreement with Daiichi Sankyo 35
Licensing Agreements 36
Eli Lilly Enters into Licensing Agreement with PeptiDream 36
Shionogi Enters into Licensing Agreement with PeptiDream 37
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 38
PeptiDream Exercises Option for Licensing Agreement with Novartis 39
PeptiDream Enters Into Licensing Agreement With Eli Lilly 40
PeptiDream Enters Into Licensing Agreement With Bristol-Myers Squibb For Peptide Discovery Platform System 41
PeptiDream Expands Agreement With Bristol-Myers Squibb For Drug Discovery 42
Equity Offering 43
PeptiDream Raises USD53 Million in IPO 43
PeptiDream Inc – Key Competitors 44
PeptiDream Inc – Key Employees 45
PeptiDream Inc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Corporate Communications 47
Aug 22, 2017: PeptiDream Appoints Representative Directors 47
Product News 48
12/16/2016: Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer 48
Other Significant Developments 49
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Merck 49
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Kyorin 50
May 31, 2017: PeptiDream Announces 5 th Milestone from Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb 51
Mar 22, 2017: PeptiDream Announces 1st Milestone from Macrocyclic Peptide Drug Discovery Alliance with Shionogi 52
Feb 14, 2017: PeptiDream Announces the Selection of Development Candidate from Discovery Collaboration with Daiichi Sankyo 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
PeptiDream Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PeptiDream Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PeptiDream Inc, Deals By Therapy Area, 2011 to YTD 2017 9
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PeptiDream to Acquire Drug Discovery Research Business from PharmaDesign 12
Taiyo Pacific Partners Acquires Minority Stake in PeptiDream 13
Bayer and PeptiDream Enter into Partnership 14
PeptiDream and Kleo Pharma Enter into Co-Development Agreement 15
Heptares Therapeutics and PeptiDream Enter into Agreement 16
Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 17
PeptiDream Enters into Agreement with Janssen Pharma 18
PeptiDream Enters into Research Agreement with BIND Therapeutics 19
PeptiDream Enters into Research Agreement with Asahi Kasei Pharma 20
PeptiDream Enters into Agreement with Genentech 21
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 22
Teijin Pharma Enters into Discovery Agreement with PeptiDream 23
PeptiDream Enters into Discovery Agreement with Sanofi 24
PeptiDream Enters into Peptide Discovery Agreement with Merck 25
PeptiDream Expands Drug Discovery Agreement with Novartis 26
PeptiDream Enters into Agreement with Tokyo Metropolitan Institute of Medical Science 27
PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 28
PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 29
PeptiDream Expands Drug Discovery Agreement with Amgen 30
PeptiDream Expands Macrocylic Peptide Drug Discovery Agreement with Novartis 31
PeptiDream Enters into Drug Discovery Agreement with MedImmune 32
PeptiDream Extends Discovery Agreement With Bristol-Myers Squibb 33
PeptiDream Enters into Drug Discovery Agreement with GlaxoSmithKline 34
PeptiDream Enters into Drug Discovery Agreement with Daiichi Sankyo 35
Eli Lilly Enters into Licensing Agreement with PeptiDream 36
Shionogi Enters into Licensing Agreement with PeptiDream 37
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 38
PeptiDream Exercises Option for Licensing Agreement with Novartis 39
PeptiDream Enters Into Licensing Agreement With Eli Lilly 40
PeptiDream Enters Into Licensing Agreement With Bristol-Myers Squibb For Peptide Discovery Platform System 41
PeptiDream Expands Agreement With Bristol-Myers Squibb For Drug Discovery 42
PeptiDream Raises USD53 Million in IPO 43
PeptiDream Inc, Key Competitors 44
PeptiDream Inc, Key Employees 45
PeptiDream Inc, Other Locations 46

★海外企業調査レポート[PeptiDream Inc (4587)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sun BioPharma Inc (SNBP):製薬・医療:M&Aディール及び事業提携情報
    Summary Sun BioPharma Inc (Sun BioPharma), formerly Cimarron Medical Inc is a biopharmaceutical company that develops disruptive therapeutics for treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101, SBP-102 and SBP-103. Its SBP-101 produces superior anti- …
  • Stantec Inc (STN):電力:M&Aディール及び事業提携情報
    Summary Stantec Inc. (Stantec) is a construction and consulting services company. The company offers architectural, engineering, and environmental services. Its service portfolio includes architecture and interior design, building engineering, community design services, geomatics, geotechnical engin …
  • Torrent Power Limited:発電所・企業SWOT分析
    Torrent Power Limited - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employe …
  • Bridgford Foods Corporation:戦略・SWOT・企業財務分析
    Bridgford Foods Corporation - Strategy, SWOT and Corporate Finance Report Summary Bridgford Foods Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Mediq NV:製薬・医療:M&Aディール及び事業提携情報
    Summary Mediq NV (Mediq) is a provider of medical devices, pharmaceuticals and related care services. It offers these services directly to people’s homes (direct), through professional healthcare customers such as hospitals and care institutions (institutional), through wholesalers or through Mediq …
  • Bioactive Bone Substitutes Plc (BONEH):企業の製品パイプライン分析
    Summary Bioactive Bone Substitutes Plc (BBS) is a health technology company that manufactures biologically active medical device implants for orthopedic surgery. The company provides technology platforms, artebone, research and development, patents, and others. It offers artebone which is made up of …
  • Mercuria Energy Group Ltd:企業の戦略的SWOT分析
    Mercuria Energy Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Destination Maternity Corporation (DEST):企業の財務・戦略的SWOT分析
    Destination Maternity Corporation (DEST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Faroe Petroleum plc (FPM):企業の財務・戦略的SWOT分析
    Summary Faroe Petroleum Plc (Faroe Petroleum) is an oil and gas company that concentrates on exploration, appraisal, development and production opportunities. The company has its exploration and development assets in the UK. Its operations portfolio consists of exploration, appraisal, development an …
  • Astellas Pharma Inc (4503):企業の財務・戦略的SWOT分析
    Astellas Pharma Inc (4503) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Otsuka Pharmaceutical Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Otsuka Pharmaceutical Co Ltd (OPC), a subsidiary of Otsuka Holdings Co Ltd is a provider of healthcare products. The company offers products which include pocari sweat, pocari sweat ion water, oronamin c, calorie mate, nature made, jerubure, jarinea, five mini, amino-value, enerugen, jog mat …
  • Bilim Pharmaceuticals:企業の戦略的SWOT分析
    Bilim Pharmaceuticals - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Indago Energy Ltd (INK):石油・ガス:M&Aディール及び事業提携情報
    Summary Indago Energy Ltd (Indago), formerly Pryme Energy Ltd is a provider of specialist oil and gas production chemicals. The company offers acquisition, up-gradation, exploration and production services to onshore oil and natural gas. It holds interests in the Newkirk project located in Kay Count …
  • Belfius Bank Sa:企業の戦略・SWOT・財務分析
    Belfius Bank Sa - Strategy, SWOT and Corporate Finance Report Summary Belfius Bank Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • OpenHydro Group Limited-エネルギー分野:企業M&A・提携分析
    Summary OpenHydro Group Limited (OpenHydro), a subsidiary of DCNS S.A. designs and manufactures marine turbines for generating renewable energy from tidal streams. The company offers installation and maintenance services for the construction of tidal farms using its Open-Centre Turbine technology. T …
  • Adocia SAS (ADOC):製薬・医療:M&Aディール及び事業提携情報
    Summary Adocia SAS (Adocia) is a biotechnology company that discovers and develops therapeutic proteins. The company provides products such as formulation of PDGF-BB for the treatment of diabetic foot ulcers. It offers novel insulin formulations for the treatment of diabetes and BioChaperone Lispro …
  • New Enterprise Associates Inc:企業のM&A・事業提携・投資動向
    New Enterprise Associates Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's New Enterprise Associates Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Reviva Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Reviva Pharmaceuticals Inc (Reviva Pharma) is a clinical development pharmaceutical company that develops therapeutic drugs. The company develops drugs in the therapeutic areas of cardiovascular, metabolic, central nervous system and inflammatory diseases. Its product pipeline comprises RP50 …
  • Challenge Group Holdings PTE. LTD.:企業の戦略・SWOT・財務情報
    Challenge Group Holdings PTE. LTD. - Strategy, SWOT and Corporate Finance Report Summary Challenge Group Holdings PTE. LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Opsens Inc (OPS):企業の財務・戦略的SWOT分析
    Summary Opsens Inc (Opsens), formerly DCB Capital Inc, is a provider of fiber optic sensing technology solutions. It focuses on fractional flow reverse guidewire in interventional cardiology. It offers OptoWire, an optical-based pressure guidewire, which enhances the clinical outcome of patients wit …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆